Corporate News

Avalo Therapeutics Inc. (AVTX) reported a decline in its share price during the trading session that concluded at 01:29 PM Central European Time on Monday, 26 November 2026. The stock fell by 6.98 % over the 24‑hour period.

At the close, one share of AVTX was priced at USD 6.93 on major exchanges. The current outstanding supply of Avalo shares is 53.6 million. The company’s market capitalization stands at USD 371.7 million, and the volume traded in the last 24 hours totaled USD 31.5 million.

From the end of the previous month to the current session, Avalo’s share price has decreased by 55.92 %. The simple moving average over the last 200 trading days is USD 16.28. Within the last 52 weeks, the highest recorded price was USD 24.27 on 5 July 2026, while the lowest price was USD 6.53 on 23 October 2026.

The following companies within the same sector experienced declines during the past 24 hours:

  • Tejon Ranch (TRC): down 0.96 %, trading at USD 16.45. Market capitalization: USD 444.5 million. P/E ratio: 74.23.
  • Vireo Growth (VREOF): down 1.92 %, trading at USD 8.17. Market capitalization: USD 444.7 million.
  • Neuropace (NPCE): down 1.75 %, trading at USD 12.91. Market capitalization: USD 443.1 million.
  • Maplight Therapeutics (MPLT): down 3.39 %, trading at USD 7.97. Market capitalization: USD 442.9 million.
  • Surrozen (SRZN): down 1.05 %, trading at USD 25.48. Market capitalization: USD 445.8 million.

Company Overview

Avalo Therapeutics Inc. is a clinical‑stage precision medicine company operating in the healthcare sector. The company focuses on the discovery, development, and commercialization of targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno‑oncology, and rare genetic diseases. Avalo serves customers worldwide and went public on the Nasdaq on 15 October 2015.